-
Company Insights
NewCorticoMetrics LLC Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our CorticoMetrics LLC Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. CorticoMetrics LLC (CorticoMetrics) is improving the state of clinical decision making in neuroradiology, augmenting qualitative assessment with quantitative analysis of magnetic resonance imaging (MRI) scans of the brain. CorticoMetrics is headquartered in Boston, Massachusetts, the US. GlobalData's Medical Devices company profile report, “CorticoMetrics LLC Pipeline Insight and Competitive Landscape, 2024" provides information about the company overview and analysis on their...
-
Company Insights
NewInlighta Biosciences LLC Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our Inlighta Biosciences LLC Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. Inlighta Biosciences LLC specializes in the development of protein-based magnetic resonance imaging (MRI) contrast agents. The company is involved in the creation of novel protein contrast agents, known as ProCA, which are designed to enhance in vivo contrast capabilities. It provides products that includes both non-targeted contrast agents for soft tissues and biomarker targeted molecular imaging contrast agents. The...
-
Sector Analysis
NewNuclear Imaging Equipment Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
Nuclear Imaging Equipment Market Report Overview The nuclear imaging equipment market size was $3.04 billion in 2023 and will grow at a CAGR of more than 6% during 2023-2033. The increase in government funding in the field of biotechnology and ongoing research on radiopharmaceuticals and their effects will propel the nuclear imaging market growth during the forecast period. Nuclear Imaging Equipment Market Outlook 2023-2033 ($ Billion) Buy the Full Report for More Insights on the Nuclear Imaging Equipment Market Forecast...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Alopecia Areata
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Alopecia Areata report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Alopecia Areata Drug Details: Upadacitinib (Rinvoq, Rim-Voq)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Vitiligo
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Vitiligo report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Vitiligo Drug Details: Upadacitinib (Rinvoq, Rim-Voq) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Systemic-Onset Juvenile Idiopathic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Hidradenitis Suppurativa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Hidradenitis Suppurativa report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Hidradenitis Suppurativa Drug Details: Upadacitinib (Rinvoq, Rim-Voq)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Oligoarticular Idiopathic Juvenile Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Oligoarticular Idiopathic Juvenile Arthritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Oligoarticular Idiopathic Juvenile Arthritis Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Systemic Lupus Erythematosus report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Systemic Lupus Erythematosus Drug Details: Upadacitinib...
-
Product Insights
NewProfound Medical Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Profound Medical Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Profound Medical Inc (Profound Medical) is a medical device company that develops and markets solutions to deliver precise ablation of the prostate. Its proprietary technology, TULSA-PRO, by combining real-time magnetic resonance imaging with transurethral, therapeutic ultrasound and closed-loop thermal feedback control enables clinicians in the ablation of malignant tissues within the prostate. Profound Medical is headquartered in Mississauga, Ontario,...